Albireo Pharma Inc Рыночная капитализация
Что обозначает Рыночная капитализация в Albireo Pharma Inc?
Рыночная капитализация Albireo Pharma Inc является $492.28M
Какое определение для Рыночная капитализация?
Рыночная капитализация - это рыночная стоимость в тот момент времени, когда акции, находящиеся в обращении публичной компании, равна цене акций в тот отрезок времени, умноженной на количество акций в обращении .
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
Рыночная капитализация компаний в Health Care сектор на NASDAQ по сравнению с Albireo Pharma Inc
Что делает Albireo Pharma Inc?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Компании с рыночная капитализация похож на Albireo Pharma Inc
- NOCIL имеет Рыночная капитализация из $491.44M
- Nektar Therapeutics имеет Рыночная капитализация из $491.50M
- Tejon Ranch Co имеет Рыночная капитализация из $491.61M
- Sisram Medical Ltd имеет Рыночная капитализация из $491.70M
- enCore имеет Рыночная капитализация из $491.81M
- Garrett Motion Inc имеет Рыночная капитализация из $491.97M
- Albireo Pharma Inc имеет Рыночная капитализация из $492.28M
- Brasilagro Companhia Brasileira De Propriedade Agricola имеет Рыночная капитализация из $492.33M
- Premier Gold Mines имеет Рыночная капитализация из $493.21M
- Beijing Enterprises Clean имеет Рыночная капитализация из $493.64M
- Xinyuan Ppty Mgmt Svc имеет Рыночная капитализация из $493.73M
- IQE Plc имеет Рыночная капитализация из $494.04M
- South Plains Inc имеет Рыночная капитализация из $494.72M